5414x

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update : Continued advancement in national programs like NIHR

"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas. Leadership Update "5414X" is the RNS (Regulatory News

: £13.0 million (+52.9%), driven by AMR and EMEAI growth.

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion . driven by AMR and EMEAI growth.

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :